173 related articles for article (PubMed ID: 22130607)
1. First chemical feature-based pharmacophore modeling of potent retinoidal retinoic acid metabolism blocking agents (RAMBAs): identification of novel RAMBA scaffolds.
Purushottamachar P; Patel JB; Gediya LK; Clement OO; Njar VC
Eur J Med Chem; 2012 Jan; 47(1):412-23. PubMed ID: 22130607
[TBL] [Abstract][Full Text] [Related]
2. Molecular recognition of CYP26A1 binding pockets and structure-activity relationship studies for design of potent and selective retinoic acid metabolism blocking agents.
Sun B; Song S; Hao CZ; Huang WX; Liu CC; Xie HL; Lin B; Cheng MS; Zhao DM
J Mol Graph Model; 2015 Mar; 56():10-9. PubMed ID: 25541526
[TBL] [Abstract][Full Text] [Related]
3. Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
Patel JB; Huynh CK; Handratta VD; Gediya LK; Brodie AM; Goloubeva OG; Clement OO; Nanne IP; Soprano DR; Njar VC
J Med Chem; 2004 Dec; 47(27):6716-29. PubMed ID: 15615521
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice.
Huynh CK; Brodie AM; Njar VC
Br J Cancer; 2006 Feb; 94(4):513-23. PubMed ID: 16449997
[TBL] [Abstract][Full Text] [Related]
5. Murine toxicology and pharmacokinetics of novel retinoic acid metabolism blocking agents.
Patel JB; Khandelwal A; Chopra P; Handratta VD; Njar VC
Cancer Chemother Pharmacol; 2007 Nov; 60(6):899-905. PubMed ID: 17345084
[TBL] [Abstract][Full Text] [Related]
6. Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases.
Njar VC; Gediya L; Purushottamachar P; Chopra P; Vasaitis TS; Khandelwal A; Mehta J; Huynh C; Belosay A; Patel J
Bioorg Med Chem; 2006 Jul; 14(13):4323-40. PubMed ID: 16530416
[TBL] [Abstract][Full Text] [Related]
7. Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy.
Clement OO; Freeman CM; Hartmann RW; Handratta VD; Vasaitis TS; Brodie AM; Njar VC
J Med Chem; 2003 Jun; 46(12):2345-51. PubMed ID: 12773039
[TBL] [Abstract][Full Text] [Related]
8. Liposomal delivery of hydrophobic RAMBAs provides good bioavailability and significant enhancement of retinoic acid signalling in neuroblastoma tumour cells.
Bilip M; Shah S; Mathiyalakan M; Tagalakis AD; Hart SL; Maeshima R; Eaton S; Orford M; Irving E; Di Florio A; Simons C; Stoker AW
J Drug Target; 2020 Jul; 28(6):643-654. PubMed ID: 31903789
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome p450 retinoic acid 4-hydroxylase inhibitors: potential agents for cancer therapy.
Njar VC
Mini Rev Med Chem; 2002 Jun; 2(3):261-9. PubMed ID: 12370067
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of amide imidazole derivatives as novel metabolic enzyme CYP26A1 inhibitors.
Sun B; Liu K; Han J; Zhao LY; Su X; Lin B; Zhao DM; Cheng MS
Bioorg Med Chem; 2015 Oct; 23(20):6763-73. PubMed ID: 26365710
[TBL] [Abstract][Full Text] [Related]
11. Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth.
Patel JB; Mehta J; Belosay A; Sabnis G; Khandelwal A; Brodie AM; Soprano DR; Njar VC
Br J Cancer; 2007 Apr; 96(8):1204-15. PubMed ID: 17387344
[TBL] [Abstract][Full Text] [Related]
12. Prospective teratology of retinoic acid metabolic blocking agents (RAMBAs) and loss of CYP26 activity.
McCaffery P; Simons C
Curr Pharm Des; 2007; 13(29):3020-37. PubMed ID: 17979744
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and CYP26A1 inhibitory activity of novel methyl 3-[4-(arylamino)phenyl]-3-(azole)-2,2-dimethylpropanoates.
Gomaa MS; Lim AS; Lau SC; Watts AM; Illingworth NA; Bridgens CE; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
Bioorg Med Chem; 2012 Oct; 20(20):6080-8. PubMed ID: 22989911
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the ligand binding site of CYP2C8 with CYP26A1 and CYP26B1: a structural basis for the identification of new inhibitors of the retinoic acid hydroxylases.
Foti RS; Diaz P; Douguet D
J Enzyme Inhib Med Chem; 2016; 31(sup2):148-161. PubMed ID: 27424662
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of LIAZAL, a retinoic acid metabolism blocking agent (RAMBA) with potential clinical applications in oncology and dermatology.
Freyne E; Raeymaekers A; Venet M; Sanz G; Wouters W; De Coster R; Wauwe JV
Bioorg Med Chem Lett; 1998 Feb; 8(3):267-72. PubMed ID: 9871667
[TBL] [Abstract][Full Text] [Related]
16. Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).
Mulvihill MJ; Kan JL; Beck P; Bittner M; Cesario C; Cooke A; Keane DM; Nigro AI; Nillson C; Smith V; Srebernak M; Sun FL; Vrkljan M; Winski SL; Castelhano AL; Emerson D; Gibson N
Bioorg Med Chem Lett; 2005 Mar; 15(6):1669-73. PubMed ID: 15745819
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors.
Aparoy P; Kumar Reddy K; Kalangi SK; Chandramohan Reddy T; Reddanna P
Bioorg Med Chem Lett; 2010 Feb; 20(3):1013-8. PubMed ID: 20045317
[TBL] [Abstract][Full Text] [Related]
18. Identification of Tazarotenic Acid as the First Xenobiotic Substrate of Human Retinoic Acid Hydroxylase CYP26A1 and CYP26B1.
Foti RS; Isoherranen N; Zelter A; Dickmann LJ; Buttrick BR; Diaz P; Douguet D
J Pharmacol Exp Ther; 2016 May; 357(2):281-92. PubMed ID: 26937021
[TBL] [Abstract][Full Text] [Related]
19. Substrate specificity and ligand interactions of CYP26A1, the human liver retinoic acid hydroxylase.
Thatcher JE; Buttrick B; Shaffer SA; Shimshoni JA; Goodlett DR; Nelson WL; Isoherranen N
Mol Pharmacol; 2011 Aug; 80(2):228-39. PubMed ID: 21521770
[TBL] [Abstract][Full Text] [Related]
20. 3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.
Mulvihill MJ; Kan JL; Cooke A; Bhagwat S; Beck P; Bittner M; Cesario C; Keane D; Lazarescu V; Nigro A; Nillson C; Panicker B; Smith V; Srebernak M; Sun FL; O'Connor M; Russo S; Fischetti G; Vrkljan M; Winski S; Castelhano AL; Emerson D; Gibson NW
Bioorg Med Chem Lett; 2006 May; 16(10):2729-33. PubMed ID: 16504501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
